---
schema_version: "secwatch.filing_event.v1"
accession: "0001200375-22-000026"
form_type: "8-K"
ticker: "CDXS"
cik: "0001200375"
company_name: "CODEXIS, INC."
filed_at: "2022-07-14T23:59:59+00:00"
generated_at: "2026-06-24T14:48:38.523956+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Codexis signs 10-year supply deal with Pfizer for PAXLOVID enzyme CDX-616; receives $25.9M retainer

## Summary
- Supply Agreement covers Codexis enzyme CDX-616 used in Pfizer's PAXLOVID (nirmatrelvir).
- Pfizer pays $25.9M retainer fee by July 31, 2022; up to 90% creditable against future orders through 2023.
- Revenue recognition: nominal portion in 2022, remainder in 2023-2024.
- No minimum purchase commitments; Codexis must maintain sufficient inventory for estimated Pfizer orders.
- Pfizer may terminate on 180 days' notice; term of 10 years with 3-year renewal options.

## SEC filing metadata
- accession: 0001200375-22-000026
- form_type: 8-K
- ticker: CDXS
- cik: 0001200375
- company_name: CODEXIS, INC.
- filed_at: 2022-07-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1200375/000120037522000026/0001200375-22-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1200375/000120037522000026/cdxs-20220714.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001200375-22-000026
- JSON: https://secwatch.observer/filing/0001200375-22-000026.json
- Plain text: https://secwatch.observer/filing/0001200375-22-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.